Clinical Guest Contributors

  1. Healing From A Pandemic And Building Resilience Into Future Clinical Trials 6/23/2020

    We must now rethink our design strategies and planning processes before starting studies to find the right fit-for-purpose virtual solutions and push the boundaries on our designs to ensure we are collecting what is truly important for research and our patients.

  2. How Trial Sites & Sponsors Can Deliver On Patient Convenience In The Age Of COVID-19 6/16/2020

    For insights on the impact of COVID-19 on patient convenience in clinical studies, and how sites and sponsors should respond, Clinical Leader reached out to Allyson Small, chief operating officer of the Society for Clinical Research Sites (SCRS) and a nearly 20-year-veteran of the healthcare industry.

  3. 6 Practical Ways To Increase Diversity In Clinical Trials 6/11/2020

    Even when a certain disease is more prevalent in a particular minority population, it can still be difficult for trial investigators to reach the right individuals. As an industry — as a group of researchers dedicating our lives to improve the health of others, regardless of their race, age, gender, or disease — how can we do better?

  4. 5 Common Challenges In Genetics-Based Clinical Trials — And How To Overcome Them 6/11/2020

    Before embarking on a genetics-based clinical trial, pharmaceutical companies should fully appreciate the unique challenges genetic information presents and implement strategies to navigate potential pitfalls. Otherwise, trial progress may slow or stall, resulting in costly study delays or even trial failures.

  5. The Expanding Role Of Artificial Intelligence In Clinical Research 6/9/2020

    While protocols and standards in clinical research have become increasingly complex, slowing progress and increasing costs, companies from startups to Big Pharma are identifying opportunities to apply AI to enhance trial efficiency, patient enrollment, and outcomes targeting.

  6. Looking Beyond The Pandemic: Ensuring Data Integrity Post-COVID-19 6/4/2020

    Trials that have continued through the pandemic are now producing data, and sponsors are having to adapt analysis and reporting strategies to fit their current circumstances. Data integrity is paramount now more than ever. This article shares strategies and processes being utilized by key players in the industry and provides insight into how to best proceed in the future.

  7. Inside Novo Nordisk’s Patient Advisory Board Meetings 6/2/2020

    Novo Nordisk's first DEEP (Disease Experience Expert People) Advisory Board meeting brought together leaders of patient organizations, patient advocates, and patients from five countries to participate in a dialogue with the company's Global Patient Relations team, project vice presidents, medical specialists, and trial managers.

  8. What Patients Are Telling Sites About Trial Participation During COVID-19 5/28/2020

    LMC Manna conducted interviews with patients who are currently enrolled in a Phase 3 clinical trial at one of their sites, with questions focusing on the impact of COVID-19 during their trial participation. Here's what they had to say.

  9. Post-COVID-19 Clinical Trials: Finally Understanding The Meaning Of Patient-Centricity 5/27/2020

    Despite being instrumental to our mission of making lifesaving therapies accessible to all, patient perspectives are far too often lost in the wake of “flashier” news about COVID-19 therapy approvals, supply chains, and scientific breakthroughs.

  10. An Update On Regulatory Guidance For U.S. Clinical Trials During COVID-19 5/21/2020

    To preserve integrity in clinical trials and mitigate the need to place clinical trials on hold indefinitely, the FDA has issued updated guidance to support important research and exploration of new treatments. Additionally, the U.S. Department of Health and Human Services’ Office of Human Research Protection issued guidance to assist researchers in applying human subject protection regulations.